<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>XYREM- sodium oxybateÂ solutionÂ </strong><br>Jazz Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use XYREM safely and effectively. See full prescribing information for XYREM.<br><br>XYREM<span class="Sup">Â®</span> (sodium oxybate) oral solution, CIII<br>Initial U.S. Approval: 2002</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: CENTRAL NERVOUS SYSTEM (CNS) <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> and MISUSE AND ABUSE.</h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> can occur with Xyrem use (<a href="#i4i_section_id_88085e0b-b875-4285-a788-3a3533b25477">5.4</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Xyrem is a Schedule III controlled substance and is the sodium salt of gamma hydroxybutyrate (GHB), a Schedule I controlled substance. Abuse or misuse of illicit GHB is associated with CNS adverse reactions, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, decreased consciousness, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (<a href="#i4i_section_id_a412568a-63f1-460f-b2fe-9ba06cbb6460">5.2</a>, <a href="#ID_537f8324-e247-4c0b-b9a0-2486775e4078">9.2</a>) </span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Because of the risks of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, abuse, and misuse, Xyrem is available only through a restricted distribution program called the Xyrem REMS Program using the central pharmacy that is specially certified. Prescribers and patients must enroll in the program. (<a href="#i4i_section_id_80a9bf53-ecb8-4892-91f6-cf4c086a7106">5.3</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">BoxedÂ Warning,Â XyremÂ REMSÂ ProgramÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 04/2015 </p>
<p class="Highlighta">IndicationsÂ andÂ Usage,Â XyremÂ REMSÂ ProgramÂ (<a href="#i4i_indications_id_0ad847bd-b20c-4b05-bd7a-248406759b7e">1</a>)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  04/2015 </p>
<p class="Highlighta">Dosage and Administration, Dose Adjustment with<br>Co-administration of Divalproex Sodium (<a href="#ID_ff9e47b9-8c57-403b-a439-7a15306fb056">2.4</a>)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â 04/2014 </p>
<p class="Highlighta">WarningsÂ andÂ Precautions,Â XyremÂ REMSÂ ProgramÂ requiredÂ componentsÂ (<a href="#i4i_section_id_80a9bf53-ecb8-4892-91f6-cf4c086a7106">5.3</a>)Â  Â Â Â 04/2015 </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: CENTRAL NERVOUS SYSTEM (CNS) <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> and MISUSE AND ABUSE.</h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> can occur with Xyrem use (<a href="#i4i_section_id_88085e0b-b875-4285-a788-3a3533b25477">5.4</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Xyrem is a Schedule III controlled substance and is the sodium salt of gamma hydroxybutyrate (GHB), a Schedule I controlled substance. Abuse or misuse of illicit GHB is associated with CNS adverse reactions, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, decreased consciousness, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (<a href="#i4i_section_id_a412568a-63f1-460f-b2fe-9ba06cbb6460">5.2</a>, <a href="#ID_537f8324-e247-4c0b-b9a0-2486775e4078">9.2</a>) </span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Because of the risks of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, abuse, and misuse, Xyrem is available only through a restricted distribution program called the Xyrem REMS Program using the central pharmacy that is specially certified. Prescribers and patients must enroll in the program. (<a href="#i4i_section_id_80a9bf53-ecb8-4892-91f6-cf4c086a7106">5.3</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Xyrem is a central nervous system depressant indicated for the treatment of:  </p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">Cataplexy</span> in <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span> (<a href="#i4i_section_id_d384381a-e583-4439-a463-e6124a88ae41">1.1</a>) </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Excessive daytime sleepiness</span> (EDS) in <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span> (<a href="#i4i_section_id_8230b073-c16e-4e58-ab00-d103ab13ada9">1.2</a>)</dd>
</dl>
<p class="Highlighta">Xyrem may only be dispensed to patients enrolled in the Xyrem REMS ProgramÂ (<a href="#i4i_indications_id_0ad847bd-b20c-4b05-bd7a-248406759b7e">1</a>). </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<dl>
<dt>â€¢</dt>
<dd>Initiate dose at 4.5 grams (g) per night administered orally in two equal, divided doses: 2.25Â g at bedtime and 2.25 g taken 2.5 to 4 hours later (<a href="#i4i_section_id_df5f04be-9a89-4373-90f6-fc33b3475bbc">2.1</a>) </dd>
<dt>â€¢</dt>
<dd>Titrate to effect in increments of 1.5 g per night at weekly intervals (0.75 g at bedtime and 0.75 g taken 2.5 to 4 hours later) (<a href="#i4i_section_id_df5f04be-9a89-4373-90f6-fc33b3475bbc">2.1</a>). </dd>
<dt>â€¢</dt>
<dd>Recommended dose range: 6 g to 9 g per night orally (<a href="#i4i_section_id_df5f04be-9a89-4373-90f6-fc33b3475bbc">2.1</a>).</dd>
</dl>
<table width="100%">
<col width="17%">
<col width="14%">
<col width="21%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="Highlighta"><span class="Bold">Total Nightly Dose</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="Highlighta"><span class="Bold">Take at Bedtime</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="Highlighta"><span class="Bold">Take 2.5 to 4 Hours Later</span> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="Highlighta">4.5 g per night </p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="Highlighta">2.25 g </p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="Highlighta">2.25 g </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="Highlighta">6 g per night </p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="Highlighta">3 g </p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="Highlighta">3 g </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="Highlighta">7.5 g per night </p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="Highlighta">3.75 g </p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="Highlighta">3.75 g </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="Highlighta">9 g per night </p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="Highlighta">4.5 g </p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="Highlighta">4.5 g </p></td>
</tr>
</tbody>
</table>
<dl>
<dt>â€¢</dt>
<dd>Take each dose while in bed and lie down after dosing (<a href="#i4i_section_id_027dc74d-aa3b-4d9d-bfa8-c0e9ff2bf584">2.2</a>).</dd>
<dt>â€¢</dt>
<dd>Allow 2 hours after eating before dosing (<a href="#i4i_section_id_027dc74d-aa3b-4d9d-bfa8-c0e9ff2bf584">2.2</a>).</dd>
<dt>â€¢</dt>
<dd>Prepare both doses prior to bedtime; dilute each dose with approximately Â¼ cup of water in pharmacy-provided vials (<a href="#i4i_section_id_027dc74d-aa3b-4d9d-bfa8-c0e9ff2bf584">2.2</a>).</dd>
<dt>â€¢</dt>
<dd>Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:  starting dose is 2.25 g per night administered orally in two equal, divided doses of approximately 1.13 g at bedtime and approximately 1.13 g taken 2.5 to 4 hours later (<a href="#i4i_section_id_9e6a98c9-6045-4e23-bfe3-198dc290b14c">2.3</a>).</dd>
<dt>â€¢</dt>
<dd>Concomitant use with divalproex sodium: an initial reduction in Xyrem dose of at least 20% is recommended (<a href="#ID_ff9e47b9-8c57-403b-a439-7a15306fb056">2.4</a>, <a href="#ID_0d200621-9945-4a87-a788-de372a3f01c1">7.2</a>).</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Oral solution, 0.5 g per mL (<a href="#i4i_dosage_form_strength_id_6ba96696-e50d-4b78-a7ab-19dd1635bdde">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Succinic semialdehyde dehydrogenase deficiency (<a href="#ID_ef177212-40b6-4099-b6c4-a121e074e3fa">4</a>) </dd>
<dt>â€¢</dt>
<dd>In combination with sedative hypnotics or alcohol (<a href="#ID_ef177212-40b6-4099-b6c4-a121e074e3fa">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>: Use caution when considering the concurrent use of Xyrem with other CNS depressants (<a href="#i4i_section_id_f40f1d8e-5167-40a0-bfc9-926b81632943">5.1</a>). </dd>
<dt>â€¢</dt>
<dd>Caution patients against hazardous activities requiring complete mental alertness or motor coordination within the first 6 hours of dosing or after first initiating treatment until certain that Xyrem does not affect them adversely (<a href="#i4i_section_id_f40f1d8e-5167-40a0-bfc9-926b81632943">5.1</a>). </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and suicidality: Monitor patients for emergent or increased <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and suicidality (<a href="#i4i_section_id_0f8a93a2-06ef-415c-8b2f-9a46ef31b8aa">5.5</a>). </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>/<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>: Monitor for impaired motor/cognitive function (<a href="#i4i_section_id_d853647a-1e19-4c0e-85a6-ff6c2501b797">5.6</a>).</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="440087" conceptname="Parasomnia">Parasomnias</span>: Evaluate episodes of sleepwalking (<a href="#i4i_section_id_d8b7ab92-23b2-4564-b34c-590157a940da">5.7</a>). </dd>
<dt>â€¢</dt>
<dd>High sodium content in Xyrem: Monitor patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (<a href="#i4i_section_id_0a937864-79bc-4f5f-8052-6abd30bae8d4">5.8</a>). </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">Most common adverse reactions (â‰¥ 5% and at least twice the incidence with placebo) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">enuresis</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> (<a href="#i4i_section_id_f505f814-2ccc-4e05-841b-ebf139b24e3f">6.1</a>).<span class="Bold"><br><br>To report SUSPECTED ADVERSE REACTIONS, contact Jazz Pharmaceuticals at 1-800-520-5568, or FDA at 1-800-FDA-1088 or www.fda.gov/Medwatch.</span> </p></div>
<div><div></div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Pregnancy: Based on animal data, may cause fetal harm (<a href="#i4i_pregnancy_id_6634426e-5fd6-4535-81fb-58c8e913ef71">8.1</a>).</dd>
<dt>â€¢</dt>
<dd>Geriatric patients: Monitor for impaired motor and/or cognitive function when taking Xyrem (<a href="#i4i_geriatric_use_id_6cc4683f-83a4-4454-86be-7d2fb188569f">8.5</a>).</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 4/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING:  CENTRAL NERVOUS SYSTEM <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> <br>and MISUSE AND ABUSE. </a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">Cataplexy</span> in <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">Narcolepsy</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Excessive Daytime Sleepiness</span> in <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">Narcolepsy</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Important Administration Instructions</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dose Modification in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-2.4" class="toc"><span class="XmChange">2.4 Dose Adjustment with Co-administration of Divalproex Sodium</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Central Nervous System <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Abuse and Misuse</a></h2>
<h2><a href="#section-5.3" class="toc"><span class="XmChange">5.3 Xyrem REMS Program</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span> and Sleep-Disordered Breathing</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and Suicidality</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Other Behavioral or Psychiatic Adverse Reactions</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="440087" conceptname="Parasomnia">Parasomnias</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Use in Patients Sensitive to High Sodium Intake</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Alcohol, Sedative Hypnotics, and CNS Depressants</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Divalproex Sodium</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse</a></h2>
<h2><a href="#section-9.3" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Human Experience</a></h2>
<h2><a href="#section-10.2" class="toc">10.2 Signs and Symptoms</a></h2>
<h2><a href="#section-10.3" class="toc">10.3 Recommended Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></a></h2>
<h2><a href="#section-10.4" class="toc">10.4 Poison Control Center</a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">Cataplexy</span> in <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">Narcolepsy</span></a></h2>
<h2><a href="#section-14.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Excessive Daytime Sleepiness</span> in <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">Narcolepsy</span></a></h2>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage</a></h2>
<h2><a href="#section-15.3" class="toc">16.3 Handling and Disposal</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-17.1" class="toc">Instructions for Use</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_b2a3d232-ad06-47f3-84ad-fa1e9f319f3a"></a><a name="section-1"></a><p></p>
<h1>WARNING:  CENTRAL NERVOUS SYSTEM <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> <br>and MISUSE AND ABUSE. </h1>
<p class="First"><span class="Bold">Xyrem (sodium oxybate) is a CNS depressant. In clinical trials at recommended doses <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">obtundation</span> and clinically significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> occurred in Xyrem-treated patients. Almost all of the patients who received Xyrem during clinical trials in <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span> were receiving central nervous system stimulants <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_f40f1d8e-5167-40a0-bfc9-926b81632943">5.1</a>)]</span></span><span class="Italics">.</span></p>
<p><span class="Bold">Xyrem<span class="Sup">Â®</span> (sodium oxybate) is the sodium salt of gamma hydroxybutyrate (GHB). Abuse of GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, decreases in the level of consciousness, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_a412568a-63f1-460f-b2fe-9ba06cbb6460">5.2</a>)].</span></span></p>
<p><span class="Bold">Because of the risks of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, abuse, and misuse, Xyrem is available only through a restricted distribution program called the Xyrem REMS Program, using the central pharmacy that is specially certified.  Prescribers and patients must enroll in the program. For further information go to <a href="http://www.XYREMREMS.com">www.XYREMREMS.com</a> or call 1-866-XYREM88<span class="Sup">Â®</span> (1-866-997-3688).Â <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_80a9bf53-ecb8-4892-91f6-cf4c086a7106">5.3</a>)].</span></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_0ad847bd-b20c-4b05-bd7a-248406759b7e"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First"><span class="Italics">Limitations of Use</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Xyrem may only be dispensed to patients enrolled in the Xyrem REMS Program <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_80a9bf53-ecb8-4892-91f6-cf4c086a7106">5.3</a>)]</span>.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d384381a-e583-4439-a463-e6124a88ae41"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">Cataplexy</span> in <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">Narcolepsy</span></h2>
<p class="First">Xyrem (sodium oxybate) oral solution is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">cataplexy</span> in <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8230b073-c16e-4e58-ab00-d103ab13ada9"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Excessive Daytime Sleepiness</span> in <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">Narcolepsy</span></h2>
<p class="First">Xyrem (sodium oxybate) oral solution is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">excessive daytime sleepiness</span> (EDS) in <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span><span class="Italics">.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_4620cd2e-e7e5-4827-9a9a-3f3599f31b53"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Healthcare professionals who prescribe Xyrem must enroll in the Xyrem REMS Program and must comply with the requirements to ensure safe use of Xyrem <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_80a9bf53-ecb8-4892-91f6-cf4c086a7106">5.3</a>)]</span>.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_df5f04be-9a89-4373-90f6-fc33b3475bbc"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing Information</h2>
<p class="First">The recommended starting dose is 4.5 grams (g) per night administered orally in two equal, divided doses: 2.25 g at bedtime and 2.25 g taken 2.5 to 4 hours later (see Table 1). Increase the dose by 1.5 g per night at weekly intervals (additional 0.75 g at bedtime and 0.75 g taken 2.5 to 4 hours later) to the effective dose range of 6 g to 9 g per night orally. Doses higher than 9 g per night have not been studied and should not ordinarily be administered.</p>
<p><span class="Bold">Table 1: Xyrem Dose Regimen (g = grams)</span></p>
<table width="100%">
<col width="27%">
<col width="13%">
<col width="19%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">If A Patientâ€™s Total Nightly Dose is:</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Take at Bedtime:</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Take 2.5 to 4 Hours Later:</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">4.5 g per night </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.25 g</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.25 g</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">6 g per night</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3 g</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3 g</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">7.5 g per night</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.75 g</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.75 g</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">9 g per night</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4.5 g</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4.5 g</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_027dc74d-aa3b-4d9d-bfa8-c0e9ff2bf584"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Important Administration Instructions</h2>
<p class="First">Take the first dose of Xyrem at least 2 hours after eating because food significantly reduces the bioavailability of sodium oxybate.  </p>
<p>Prepare both doses of Xyrem prior to bedtime. Prior to ingestion, each dose of Xyrem should be diluted with approximately Â¼ cup (approximately 60 mL) of water in the empty pharmacy vials provided. Patients should take both doses of Xyrem while in bed and lie down immediately after dosing as Xyrem may cause them to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep abruptly without first feeling drowsy.  Patients will often <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep within 5 minutes of taking Xyrem, and will usually <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep within 15 minutes, though the time it takes any individual patient to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep may vary from night to night.  Patients should remain in bed following ingestion of the first and second doses, and should not take the second dose until 2.5 to 4 hours after the first dose. Patients may need to set an alarm to awaken for the second dose. Rarely, patients may take up to 2 hours to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9e6a98c9-6045-4e23-bfe3-198dc290b14c"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dose Modification in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The recommended starting dose in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is 2.25 g per night administered orally in two equal, divided doses: approximately 1.13 g at bedtime and approximately 1.13 g taken 2.5 to 4 hours later <span class="Italics">[see Use in Specific Populations (<a href="#i4i_section_id_61053043-317b-41fc-a311-5ff35d24844c">8.6</a>); Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_bbdf2dd9-c8db-4e38-ba5c-98895acba319">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ff9e47b9-8c57-403b-a439-7a15306fb056"></a><a name="section-2.4"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">2.4 Dose Adjustment with Co-administration of Divalproex Sodium</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Pharmacokinetic and <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interactions</span> have been observed when Xyrem is co-administered with divalproex sodium. For patients already stabilized on Xyrem, it is recommended that addition of divalproex sodium should be accompanied by an initial reduction in the nightly dose of Xyrem by at least 20%. For patients already taking divalproex sodium, it is recommended that prescribers use a lower starting Xyrem dose with introducing Xyrem. Prescribers should monitor patient response and adjust dose accordingly [<span class="Italics">see Drug Interactions (<a href="#ID_0d200621-9945-4a87-a788-de372a3f01c1">7.2</a>)</span> and <span class="Italics">Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_bbdf2dd9-c8db-4e38-ba5c-98895acba319">12.3</a>)</span>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_6ba96696-e50d-4b78-a7ab-19dd1635bdde"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Xyrem is a clear to slightly opalescent oral solution, in a concentration of 0.5 g per mL.  </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_ef177212-40b6-4099-b6c4-a121e074e3fa"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<dl>
<dt>â€¢</dt>
<dd>Xyrem is contraindicated in patients being treated with sedative hypnotic agents.</dd>
<dt>â€¢</dt>
<dd>Patients should not drink alcohol when using Xyrem.</dd>
<dt>â€¢</dt>
<dd>Xyrem is contraindicated in patients with succinic semialdehyde dehydrogenase deficiency.  This is a rare disorder of inborn error of metabolism variably characterized by <span class="product-label-link" type="condition" conceptid="440389" conceptname="Mental retardation">mental retardation</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, and <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_8cf09a26-0ec1-448d-91c0-d3a8d41ef42a"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f40f1d8e-5167-40a0-bfc9-926b81632943"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Central Nervous System <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></h2>
<p class="First">Xyrem is a central nervous system (CNS) depressant.  Alcohol and sedative hypnotics are contraindicated in patients who are using Xyrem. The concurrent use of Xyrem with other CNS depressants, including but not limited to opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating anti-epileptic drugs, general anesthetics, muscle relaxants, and/or illicit CNS depressants, may increase the risk of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, profound sedation, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  If use of these CNS depressants in combination with Xyrem is required, dose reduction or discontinuation of one or more CNS depressants (including Xyrem) should be considered. In addition, if short-term use of an opioid (e.g. post- or perioperative) is required, interruption of treatment with Xyrem should be considered.  </p>
<p>Healthcare providers should caution patients about operating hazardous machinery, including automobiles or airplanes, until they are reasonably certain that Xyrem does not affect them adversely (e.g., impair judgment, thinking, or motor skills).  Patients should not engage in hazardous occupations or activities requiring complete mental alertness or motor coordination, such as operating machinery or a motor vehicle or flying an airplane, for at least 6 hours after taking the second nightly dose of Xyrem.  Patients should be queried about <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span><span class="Bold">â€?</span>related events upon initiation of Xyrem therapy and periodically thereafter <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_80a9bf53-ecb8-4892-91f6-cf4c086a7106">5.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a412568a-63f1-460f-b2fe-9ba06cbb6460"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Abuse and Misuse</h2>
<p class="First">Xyrem is a Schedule III controlled substance.  The active ingredient of Xyrem, sodium oxybate or gamma-hydroxybutyrate (GHB), is a Schedule I controlled substance. Abuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, decreases in the level of consciousness, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The rapid onset of sedation, coupled with the amnestic features of Xyrem, particularly when combined with alcohol, has proven to be dangerous for the voluntary and involuntary user (e.g., <span class="product-label-link" type="condition" conceptid="439237" conceptname="Assault">assault</span> victim).  Because illicit use and abuse of GHB have been reported, physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of GHB (e.g. increase in size or frequency of dosing, drug-seeking behavior, feigned <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">cataplexy</span>)<span class="Italics"> [see Warnings and Precautions (<a href="#i4i_section_id_80a9bf53-ecb8-4892-91f6-cf4c086a7106">5.3</a>) </span>and<span class="Italics"> Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (<a href="#ID_537f8324-e247-4c0b-b9a0-2486775e4078">9.2</a>)]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_80a9bf53-ecb8-4892-91f6-cf4c086a7106"></a><a name="section-5.3"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.3 Xyrem REMS Program</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Because of the risks of central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and abuse/misuse, Xyrem is available only through a restricted distribution program called the Xyrem REMS Program.   </span></p>
<p style="border-left:1px solid;"><span class="XmChange">Required components of the Xyrem REMS Program include:</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="XmChange">Healthcare Providers who prescribe Xyrem are specially certified</span></dd>
<dt>â€¢</dt>
<dd><span class="XmChange">Xyrem will be dispensed only by the central pharmacy that is specially  certified</span></dd>
<dt>â€¢</dt>
<dd><span class="XmChange">Xyrem will be dispensed and shipped only to patients who are enrolled in the XYREM REMS Program with documentation of safe use </span></dd>
</dl>
<p style="border-left:1px solid;"><span class="XmChange">Further information is available at </span><span class="XmChange"><a href="http://www.XYREM.com">www.XYREMREMS.com</a></span><span class="XmChange"> or <span class="Bold">1-866-XYREM88<span class="Sup">Â®</span> (1-866-997-3688)</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_88085e0b-b875-4285-a788-3a3533b25477"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span> and Sleep-Disordered Breathing</h2>
<p class="First">       Xyrem may impair respiratory drive, especially in patients with compromised respiratory function. In <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>, life-threatening <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> has been reported <span class="Italics">[see Overdosage (<a href="#i4i_overdosage_id_b9d3653c-35c2-4c13-b43d-48152a1b9279">10</a>)]. </span></p>
<p>       In a study assessing the respiratory-depressant effects of Xyrem at doses up to 9 g per night in 21 patients with <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span>, no dose-related changes in oxygen saturation were demonstrated in the group as a whole. One of the four patients with preexisting, moderate-to-severe <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span> had significant worsening of the <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>/<span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">hypopnea</span> index during treatment.</p>
<p>      In a study assessing the effects of Xyrem 9 g per night in 50 patients with obstructive <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span>, Xyrem did not increase the severity of sleep-disordered breathing and did not adversely affect the average duration and severity of oxygen desaturation overall.  However, there was a significant increase in the number of central <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apneas</span> in patients taking Xyrem, and clinically significant oxygen desaturation (â‰¤Â 55%) was measured in three patients (6%) after Xyrem administration, with one patient withdrawing from the study and two continuing after single brief instances of desaturation.  Prescribers should be aware that increased central <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apneas</span> and clinically relevant desaturation events have been observed with Xyrem administration.  </p>
<p>       In clinical trials in 128 patients with <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span>, two subjects had profound <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, which resolved after supportive respiratory intervention. Two other patients discontinued sodium oxybate because of severe <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span> and an increase in obstructive <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span>. In two controlled trials assessing polysomnographic (PSG) measures in patients with <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span>, 40 of 477 patients were included with a baseline <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>/<span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">hypopnea</span> index of 16 to 67 events per hour, indicative of mild to severe sleep-disordered breathing. None of the 40 patients had a clinically significant worsening of respiratory function as measured by <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>/<span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">hypopnea</span> index and pulse oximetry at doses of 4.5 g to 9 g per night.</p>
<p>       Prescribers should be aware that sleep-related breathing disorders tend to be more prevalent in obese patients and in postmenopausal women not on hormone replacement therapy as well as among patients with <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0f8a93a2-06ef-415c-8b2f-9a46ef31b8aa"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and Suicidality</h2>
<p class="First">       In clinical trials in patients with <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span> (n=781), there were two <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> and two <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">attempted suicides</span> in Xyrem-treated patients, including three patients with a previous history of depressive psychiatric disorder. Of the two <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span>, one patient used Xyrem in conjunction with other drugs. Xyrem was not involved in the second <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.  Adverse reactions of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> were reported by 7% of 781 Xyrem-treated patients, with four patients (&lt; 1%) discontinuing because of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. In most cases, no change in Xyrem treatment was required.</p>
<p>       In a controlled trial, with patients randomized to fixed doses of 3 g, 6 g, or 9 g per night Xyrem or placebo, there was a single event of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> at the 3 g per night dose.  In another controlled trial, with patients titrated from an initial 4.5 g per night starting dose, the incidences of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> were 1 (1.7%), 1 (1.5%), 2 (3.2%), and 2 (3.6%) for the placebo, 4.5Â g, 6 g, and 9 g per night doses, respectively.</p>
<p>      The emergence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> in patients treated with Xyrem requires careful and immediate evaluation. Patients with a previous history of a <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive illness</span> and/or <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> should be monitored carefully for the emergence of <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> while taking Xyrem.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d853647a-1e19-4c0e-85a6-ff6c2501b797"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Other Behavioral or Psychiatic Adverse Reactions</h2>
<p class="First">During clinical trials in <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span>, 3% of 781 patients treated with Xyrem experienced <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, with incidence generally increasing with dose. </p>
<p>Less than 1% of patients discontinued the drug because of <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>. <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span> was reported at all recommended doses from 6 g to 9 g per night.  In a controlled trial where patients were randomized to fixed total daily doses of 3 g, 6 g, or 9 g per night or placebo, a dose-response relationship for <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> was demonstrated, with 17% of patients at 9 g per night experiencing <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.  In all cases in that controlled trial, the <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> resolved soon after termination of treatment.  In Trial 3 where sodium oxybate was titrated from an initial 4.5 g per night dose, there was a single event of <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> in one patient at the 9 g per night dose.  In the majority of cases in all clinical trials in <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> resolved either soon after termination of dosing or with continued treatment.  However, patients treated with Xyrem who become <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span> should be evaluated fully, and appropriate intervention considered on an individual basis. </p>
<p><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> occurred in 5.8% of the 874 patients receiving Xyrem in clinical trials in another population.  The emergence of or increase in <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> in patients taking Xyrem should be carefully monitored.  </p>
<p>Other neuropsychiatric reactions reported in Xyrem clinical trials included <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>. The emergence of thought disorders and/or behavior abnormalities requires careful and immediate evaluation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d8b7ab92-23b2-4564-b34c-590157a940da"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="440087" conceptname="Parasomnia">Parasomnias</span></h2>
<p class="First">Sleepwalking, defined as <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span> behavior occurring at night and at times associated with <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">wandering</span>, was reported in 6% of 781 patients with <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span> treated with Xyrem in controlled and long-term open-label studies, with &lt; 1% of patients discontinuing due to sleepwalking. Rates of sleepwalking were similar for patients taking placebo and patients taking Xyrem in controlled trials.  It is unclear if some or all of the reported sleepwalking episodes correspond to true <span class="product-label-link" type="condition" conceptid="377535" conceptname="Sleep walking disorder">somnambulism</span>, which is a <span class="product-label-link" type="condition" conceptid="440087" conceptname="Parasomnia">parasomnia</span> occurring during non-REM sleep, or to any other specific medical disorder. Five instances of significant injury or potential injury were associated with sleepwalking during a clinical trial of Xyrem in patients with <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="440087" conceptname="Parasomnia">Parasomnias</span> including sleepwalking have been reported in postmarketing experience with Xyrem. Therefore, episodes of sleepwalking should be fully evaluated and appropriate interventions considered. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0a937864-79bc-4f5f-8052-6abd30bae8d4"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Use in Patients Sensitive to High Sodium Intake</h2>
<p class="First">Xyrem has a high salt content.  In patients sensitive to salt intake (e.g., those with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>) consider the amount of daily sodium intake in each dose of Xyrem.  Table 2 provides the approximate sodium content per Xyrem dose.<br><br><span class="Bold">Table 2</span></p>
<p><span class="Bold">Approximate Sodium Content per Total Nightly Dose of Xyrem (g = grams)</span><br></p>
<table width="100%">
<col width="25%">
<col width="35%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Xyrem Dose </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Sodium Content/Total Nightly Exposure</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3 g per night</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">550 mg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4.5 g per night</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">820 mg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6 g  per night</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1100 mg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7.5 g per night</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1400 mg</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">9 g per night</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1640 mg</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_c2546612-c606-4f81-8fd1-e4a4cded256f"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions appear in other sections of the labeling:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_f40f1d8e-5167-40a0-bfc9-926b81632943">5.1</a>)]</span>
</dd>
<dt>â€¢</dt>
<dd>Abuse and Misuse <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_a412568a-63f1-460f-b2fe-9ba06cbb6460">5.2</a>)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span> and Sleep-disordered Breathing <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_88085e0b-b875-4285-a788-3a3533b25477">5.4</a>)] </span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and Suicidality <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_0f8a93a2-06ef-415c-8b2f-9a46ef31b8aa">5.5</a>)]</span>
</dd>
<dt>â€¢</dt>
<dd>Other Behavioral or Psychiatric Adverse Reactions<span class="Italics"> [see Warnings and Precautions (<a href="#i4i_section_id_d853647a-1e19-4c0e-85a6-ff6c2501b797">5.6</a>)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="440087" conceptname="Parasomnia">Parasomnias</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_d8b7ab92-23b2-4564-b34c-590157a940da">5.7</a>)]</span>
</dd>
<dt>â€¢</dt>
<dd>Use in Patients Sensitive to High Sodium Intake <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_0a937864-79bc-4f5f-8052-6abd30bae8d4">5.8</a>)]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f505f814-2ccc-4e05-841b-ebf139b24e3f"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>Xyrem was studied in three placebo-controlled clinical trials (Trials N1, N3, and N4, described in <a href="#ID_d9c75604-4c43-45bd-9ab2-2adfca852e6f">Sections 14.1</a> and <a href="#ID_3f4dc2ed-beb5-452e-867d-03c2496fb777">14.2</a>) in 611 patients with <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span> (398 subjects treated with Xyrem, and 213 with placebo). A total of 781 patients with <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span> were treated with Xyrem in controlled and uncontrolled clinical trials.</p>
<p>Section 6.1 and Table 3 presents adverse reactions from three pooled, controlled trials (N1, N3, N4) in patients with <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span>.</p>
<p><span class="Italics">Adverse Reactions Leading to Treatment Discontinuation: </span></p>
<p>Of the 398 Xyrem-treated patients with <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span>, 10.3% of patients discontinued because of adverse reactions compared with 2.8% of patients receiving placebo. The most common adverse reaction leading to discontinuation was <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (2.8%). The majority of adverse reactions leading to discontinuation began during the first few weeks of treatment.</p>
<p><span class="Italics">CommonlyÂ Observed Adverse Reactions in Controlled Clinical Trials:</span></p>
<p>The most common adverse reactions (incidence â‰¥ 5% and twice the rate seen with placebo) in Xyrem-treated patients were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">enuresis</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>.</p>
<p><span class="Italics">Adverse Reactions Occurring at an Incidence of 2% or greater:</span></p>
<p>Table 3 lists adverse reactions that occurred at a frequency of 2% or more in any treatment group for three controlled trials and were more frequent in any Xyrem treatment group than with placebo. Adverse reactions are summarized by dose at onset. Nearly all patients in these studies initiated treatment at 4.5 g per night. In patients who remained on treatment, adverse reactions tended to occur early and to diminish over time.<br><br><span class="Bold">Table 3</span><br><span class="Bold">Adverse Reactions Occurring in â‰¥2% of Patients and More Frequently with Xyrem than Placebo in Three Controlled Trials (N1, N3, N4) by Body System and Dose at Onset</span></p>
<table width="100%">
<col width="31%">
<col width="14%">
<col width="15%">
<col width="14%">
<col width="15%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">System Organ Class/MedDRA Preferred Term </span></th>
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Placebo </span><br><span class="Bold">(n=213) %</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Xyrem 4.5g</span><br><span class="Bold">(n=185) %</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Xyrem 6g</span><br><span class="Bold">(n=258)Â %</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Xyrem 9g </span><br><span class="Bold">(n=178) %</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">ANY ADVERSE REACTION</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">62</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">45</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">55</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">70</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">GASTROINTESTINAL DISORDERS</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">20</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">11</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">GENERAL DISORDERS AND ADMINISTRATIVE SITE CONDITIONS</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4012565" conceptname="Feeling intoxicated">Feeling drunk</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">MUSCULOSKELETAL AND <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">CONNECTIVE TISSUE DISORDERS</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">Cataplexy</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">NERVOUS SYSTEM DISORDERS</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">15</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">Disturbance in attention</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="435238" conceptname="Sleep paralysis">Sleep paralysis</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">PSYCHIATRIC DISORDERS</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">Disorientation</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">&lt; 1 </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="377535" conceptname="Sleep walking disorder">Sleep walking</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">RENAL AND URINARY DISORDERS</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">Enuresis</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">SKIN AND SUBCUTANEOUS TISSUE DISORDERS</span></p></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics">Dose-Response Information</span></p>
<p>In clinical trials in <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span>, a dose-response relationship was observed for <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">disturbance in attention</span>, <span class="product-label-link" type="condition" conceptid="4012565" conceptname="Feeling intoxicated">feeling drunk</span>, sleepwalking, and <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">enuresis</span>. The incidence of all these reactions was notably higher at 9 g per night.</p>
<p>In controlled trials in <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span>, discontinuations of treatment due to adverse reactions were greater at higher doses of Xyrem.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b42194cc-5dcb-4d43-8561-6125d0c9b2ec"></a><a name="section-6.1.1"></a><p></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6c09f5b6-60dc-425f-a3d8-99b981179bb9"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following additional adverse reactions that have a likely causal relationship to Xyrem exposure have been identified during postmarketing use of Xyrem. These adverse reactions include: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span>, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, <span class="product-label-link" type="condition" conceptid="4137607" conceptname="Hangover">hangover</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attack</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>, and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreased</span>. Because these reactions are reported voluntarily, it is not always possible to reliably estimate their frequency.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_fd2a0d80-5184-43c7-99cc-7e7853b3c3d3"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cd97b2c1-133d-414e-a2f3-0df3c3660e85"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Alcohol, Sedative Hypnotics, and CNS Depressants</h2>
<p class="First">Xyrem should not be used in combination with alcohol or sedative hypnotics.  Use of other CNS depressants may potentiate the CNS-depressant effects of Xyrem.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0d200621-9945-4a87-a788-de372a3f01c1"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Divalproex Sodium</h2>
<p class="First">Concomitant use of Xyrem with divalproex sodium resulted in a 25% mean increase in systemic exposure to Xyrem (AUC ratio range of 0.8 to 1.7) and in a greater impairment on some tests of attention and working memory. An initial Xyrem dose reduction of at least 20% is recommended if divalproex sodium is prescribed to patients already taking Xyrem <span class="Italics">[see Dosage and Administration (<a href="#ID_ff9e47b9-8c57-403b-a439-7a15306fb056">2.4</a>) </span>and<span class="Italics"> Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_bbdf2dd9-c8db-4e38-ba5c-98895acba319">12.3</a>)].</span>  Prescribers are advised to monitor patient response closely and adjust dose accordingly if concomitant use of Xyrem and divalproex sodium is warranted.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_5b81c737-14b8-44a6-a0ef-e31e6d8b7cc3"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_6634426e-5fd6-4535-81fb-58c8e913ef71"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category C</span></p>
<p>There are no adequate and well-controlled studies in pregnant women. Xyrem should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Oral administration of sodium oxybate to pregnant rats (150, 350, or 1,000 mg/kg/day) or rabbits (300, 600, or 1,200Â mg/kg/day) throughout organogenesis produced no clear evidence of developmental toxicity. The highest doses tested in rats and rabbits were approximately 1 and 3 times, respectively, the maximum recommended human dose (MRHD) of 9 g per night on a body surface area (mg/m<span class="Sup">2</span>) basis.</p>
<p>Oral administration of sodium oxybate (150, 350, or 1,000Â mg/kg/day) to rats throughout pregnancy and lactation resulted in increased <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> and decreased offspring postnatal viability and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> at the highest dose tested. The no-effect dose for pre- and post-natal developmental toxicity in rats is less than the MRHD on a mg/m<span class="Sup">2</span> basis.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="ID_bba48b1c-4e90-43f9-ad04-879d175ca680"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">Xyrem has not been studied in labor or delivery. In obstetric anesthesia using an injectable formulation of sodium oxybate, newborns had stable cardiovascular and respiratory measures but were very <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>, causing a slight decrease in Apgar scores. There was a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in the rate of uterine contractions 20 minutes after injection. Placental transfer is rapid, but umbilical vein levels of sodium oxybate were no more than 25% of the maternal concentration. No sodium oxybate was detected in the infantâ€™s blood 30 minutes after delivery. Elimination curves of sodium oxybate between a 2-day-old infant and a 15-year-old patient were similar. Subsequent effects of sodium oxybate on later growth, development, and maturation in humans are unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_8409c6f4-7c74-441e-9ff2-339156c07190"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether sodium oxybate is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Xyrem is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_fb29baf6-88cb-4e7a-a151-4dca2466eaad"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_6cc4683f-83a4-4454-86be-7d2fb188569f"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of Xyrem in patients with <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span> did not include sufficient numbers of subjects age 65 years and older to determine whether they respond differently from younger subjects. In controlled trials in another population, 39 (5%) of 874 patients were 65 years or older. Discontinuations of treatment due to adverse reactions were increased in the elderly compared to younger adults (20.5% v. 18.9%).  Frequency of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> was markedly increased in the elderly (38.5% v. 18.9%).  The most common adverse reactions were similar in both age categories. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_61053043-317b-41fc-a311-5ff35d24844c"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The starting dose of Xyrem should be reduced by one-half in patients with liver impairment <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_id_9e6a98c9-6045-4e23-bfe3-198dc290b14c">2.3</a>) </span>and<span class="Italics"> Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_bbdf2dd9-c8db-4e38-ba5c-98895acba319">12.3</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_id_6f439f92-7a91-45a7-8dff-3991d92e7172"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="i4i_controlled_substance_id_d5136fc3-8e7b-4d7a-9493-fc33298beb34"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance</h2>
<p class="First">Xyrem is a Schedule III controlled substance under the Federal Controlled Substances Act.  Non-medical use of Xyrem could lead to penalties assessed under the higher ScheduleÂ I controls.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="ID_537f8324-e247-4c0b-b9a0-2486775e4078"></a><a name="section-9.2"></a><p></p>
<h2>9.2 Abuse</h2>
<p class="First">Xyrem (sodium oxybate), the sodium salt of GHB, produces dose-dependent central nervous system effects, including hypnotic and positive subjective reinforcing effects. The onset of effect is rapid, enhancing its potential for abuse or misuse.</p>
<p>The rapid onset of sedation, coupled with the amnestic features of Xyrem, particularly when combined with alcohol, has proven to be dangerous for the voluntary and involuntary user (e.g., <span class="product-label-link" type="condition" conceptid="439237" conceptname="Assault">assault</span> victim).</p>
<p>Illicit GHB is abused in social settings primarily by young adults.  Some of the doses estimated to be abused are in a similar dosage range to that used for treatment of patients with <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">cataplexy</span>. GHB has some commonalities with ethanol over a limited dose range, and some cross tolerance with ethanol has been reported as well.  Cases of severe <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and craving for GHB have been reported when the drug is taken around the clock.  Patterns of abuse indicative of <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> include: 1) the use of increasingly large doses, 2)Â increased frequency of use, and 3) continued use despite adverse consequences.  </p>
<p>Because illicit use and abuse of GHB have been reported, physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of GHB (e.g. increase in size or frequency of dosing, drug-seeking behavior, feigned <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">cataplexy</span>). Dispose of Xyrem according to state and federal regulations. It is safe to dispose of Xyrem down the sanitary sewer.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="ID_20fee021-c2bf-4367-9bd6-9572a17c2b89"></a><a name="section-9.3"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">There have been case reports of withdrawal, ranging from mild to severe, following discontinuation of illicit use of GHB at frequent repeated doses (18 g to 250 g per day) in excess of the therapeutic dose range.  Signs and symptoms of GHB withdrawal following abrupt discontinuation included <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, rebound <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, and, particularly in the case of severe withdrawal, <span class="product-label-link" type="condition" conceptid="4275889" conceptname="Visual hallucinations">visual hallucinations</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, and <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>.  These symptoms generally abated in 3 to 14 days. In cases of severe withdrawal, hospitalization may be required. The discontinuation effects of Xyrem have not been systematically evaluated in controlled clinical trials.  In the clinical trial experience with Xyrem in <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span>/<span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">cataplexy</span> patients at therapeutic doses, two patients reported <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and one reported <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> following abrupt discontinuation at the termination of the clinical trial; in the two patients with <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, the frequency of <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">cataplexy</span> had increased markedly at the same time.</p>
<p><span class="Italics">Tolerance</span></p>
<p>Tolerance to Xyrem has not been systematically studied in controlled clinical trials. There have been some case reports of symptoms of tolerance developing after illicit use at dosages far in excess of the recommended Xyrem dosage regimen.  Clinical studies of sodium oxybate in the treatment of alcohol withdrawal suggest a potential cross-tolerance with alcohol. The safety and effectiveness of Xyrem in the treatment of alcohol withdrawal have not been established. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_b9d3653c-35c2-4c13-b43d-48152a1b9279"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c4903f89-0502-439b-9312-aedd80e2070c"></a><a name="section-10.1"></a><p></p>
<h2>10.1 Human Experience</h2>
<p class="First">Information regarding <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with Xyrem is derived largely from reports in the medical literature that describe symptoms and signs in individuals who have ingested GHB illicitly.  In these circumstances the co-ingestion of other drugs and alcohol was common, and may have influenced the presentation and severity of clinical manifestations of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. </p>
<p>In clinical trials two cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with Xyrem were reported.  In the first case, an estimated dose of 150 g, more than 15 times the maximum recommended dose, caused a patient to be unresponsive with brief periods of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> and to be <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinent</span> of urine and feces.  This individual recovered without sequelae.  In the second case, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was reported following a <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdose</span> consisting of Xyrem and numerous other drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_22b971b1-cd2f-46be-b409-3faa4c36f7d6"></a><a name="section-10.2"></a><p></p>
<h2>10.2 Signs and Symptoms</h2>
<p class="First">Information about signs and symptoms associated with overdosage with Xyrem derives from reports of its illicit use.  Patient presentation following <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is influenced by the dose ingested, the time since ingestion, the co-ingestion of other drugs and alcohol, and the fed or fasted state.  Patients have exhibited varying degrees of depressed consciousness that may fluctuate rapidly between a confusional, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> combative state with <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> (even when obtunded), <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and impaired psychomotor skills have been observed.  No typical pupillary changes have been described to assist in diagnosis; pupillary reactivity to light is maintained.  <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span> has been reported.  An increasing depth of <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> has been observed at higher doses.  <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">Myoclonus</span> and tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span> have been reported.  Respiration may be unaffected or compromised in rate and depth.  Cheyne-Stokes respiration and <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> have been observed.  <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> and <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span> may accompany <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>, as well as muscular <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, but tendon reflexes remain intact.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e3607d02-9486-4369-8cf9-7703bf547420"></a><a name="section-10.3"></a><p></p>
<h2>10.3 Recommended Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></h2>
<p class="First">General symptomatic and supportive care should be instituted immediately, and gastric decontamination may be considered if co-ingestants are suspected.  Because <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> may occur in the presence of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">obtundation</span>, appropriate posture (left lateral recumbent position) and protection of the airway by intubation may be warranted.  Although the gag reflex may be absent in deeply <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">comatose</span> patients, even <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span> patients may become combative to intubation, and rapid-sequence induction (without the use of sedative) should be considered.  Vital signs and consciousness should be closely monitored.  The <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> reported with GHB <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> has been responsive to atropine intravenous administration.  No reversal of the central depressant effects of Xyrem can be expected from naloxone or flumazenil administration.  The use of hemodialysis and other forms of extracorporeal drug removal have not been studied in GHB <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.  However, due to the rapid metabolism of sodium oxybate, these measures are not warranted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f2ae751b-1d36-4cc1-a680-60f0e3b3cd8f"></a><a name="section-10.4"></a><p></p>
<h2>10.4 Poison Control Center</h2>
<p class="First">As with the management of all cases of drug overdosage, the possibility of multiple drug ingestion should be considered.  The healthcare provider is encouraged to collect urine and blood samples for routine toxicologic screening, and to consult with a regional poison control center (1-800-222-1222) for current treatment recommendations.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_f8b62f4e-a47e-4a60-85f1-71e098162a28"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Sodium oxybate, a CNS depressant, is the active ingredient in Xyrem. The chemical name for sodium oxybate is sodium 4-hydroxybutyrate. The molecular formula is C<span class="Sub">4</span>H<span class="Sub">7</span>NaO<span class="Sub">3</span>, and the molecular weight is 126.09 g/mole. The chemical structure is:</p>
<div class="Figure">
<a name="id1683247962"></a><img alt="chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=926eb076-a4a8-45e4-91ef-411f0aa4f3ca&amp;name=image-01.jpg">
</div>
<p>Sodium oxybate is a white to off-white, crystalline powder that is very soluble in aqueous solutions. Each mL of Xyrem contains 0.5 g of sodium oxybate in USP Purified Water, neutralized to pH 7.5 with malic acid.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_db17d6f8-7458-493e-bbe9-b01c5316082e"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_ba9ada5e-9143-47a7-87f2-2c98f6e66682"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Xyrem is a CNS depressant. The mechanism of action of Xyrem in the treatment of <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span> is unknown. Sodium oxybate is the sodium salt of gamma hydroxybutyrate, an endogenous compound and metabolite of the neurotransmitter GABA.  It is hypothesized that the therapeutic effects of Xyrem on <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">cataplexy</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">excessive daytime sleepiness</span> are mediated through GABA<span class="Sub">B</span> actions at noradrenergic and dopaminergic neurons, as well as at thalamocortical neurons.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_bbdf2dd9-c8db-4e38-ba5c-98895acba319"></a><a name="section-12.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2776a625-850f-4a14-9d64-038e0840846c"></a><a name="section-12.2.1"></a><p></p>
<h3>Pharmacokinetics of sodium oxybate are nonlinear and are similar following single or repeat dosing.</h3>
<p class="First"><span class="Italics">Absorption</span></p>
<p>Following oral administration, sodium oxybate is absorbed rapidly across the clinical dose range, with an absolute bioavailability of about 88%. The average peak plasma concentrations (C<span class="Sub">max</span>) following administration of each of the two 2.25 g doses given under fasting conditions 4 hours apart were similar. The average time to peak plasma concentration (T<span class="Sub">max</span>) ranged from 0.5 to 1.25 hours. Following oral administration, the plasma levels of sodium oxybate increased more than dose-proportionally, with blood levels increasing 3.7<span class="Bold">â€?</span>fold as total daily dose is doubled from 4.5 g to 9 g. Single doses greater than 4.5 g have not been studied. Administration of Xyrem immediately after a high-fat meal resulted in delayed absorption (average T<span class="Sub">max</span> increased from 0.75 hr to 2 hr) and a reduction in C<span class="Sub">max</span> by a mean of 59% and of systemic exposure (AUC) by 37%. <br></p>
<p><span class="Italics">Distribution</span></p>
<p>Sodium oxybate is a hydrophilic compound with an apparent volume of distribution averaging 190 mL/kg to 384 mL/kg. At sodium oxybate concentrations ranging from 3Â mcg/mL to 300 mcg/mL, less than 1% is bound to plasma proteins.<br></p>
<p><span class="Italics">Metabolism</span></p>
<p>Animal studies indicate that metabolism is the major elimination pathway for sodium oxybate, producing <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> and water via the tricarboxylic acid (Krebs) cycle and secondarily by beta-oxidation. The primary pathway involves a cytosolic NADP<span class="Sup">+</span>-linked enzyme, GHB dehydrogenase, that catalyzes the conversion of sodium oxybate to succinic semialdehyde, which is then biotransformed to succinic acid by the enzyme succinic semialdehyde dehydrogenase. Succinic acid enters the Krebs cycle where it is metabolized to <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> and water. A second mitochondrial oxidoreductase enzyme, a transhydrogenase, also catalyzes the conversion to succinic semialdehyde in the presence of Î±-ketoglutarate. An alternate pathway of biotransformation involves Î²-oxidation via 3,4-dihydroxybutyrate to <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> and water. No active metabolites have been identified.<br></p>
<p><span class="Italics">Elimination</span></p>
<p>The clearance of sodium oxybate is almost entirely by biotransformation to <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span>, which is then eliminated by expiration. On average, less than 5% of unchanged drug appears in human urine within 6 to 8 hours after dosing. Fecal excretion is negligible. Sodium oxybate has an elimination half-life of 0.5 to 1 hour.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a7d2c204-caf2-4366-9e49-895bd4b63491"></a><a name="section-12.2.2"></a><p></p>
<h3><span class="Bold">Specific Populations</span></h3>
<p class="First"><span class="Italics">Geriatric</span></p>
<p>There is limited experience with Xyrem in the elderly. Results from a pharmacokinetic study (n=20) in another studied population indicate that the pharmacokinetic characteristics of sodium oxybate are consistent among younger (age 48 to 64 years) and older (age 65 to 75 years) adults. <br></p>
<p><span class="Italics">Pediatric</span></p>
<p>The pharmacokinetics of sodium oxybate in patients younger than 18 years of age have not been studied. <br></p>
<p><span class="Italics">Gender</span></p>
<p>In a study of 18 female and 18 male healthy adult volunteers, no gender differences were detected in the pharmacokinetics of sodium oxybate oral solution following a single oral dose of 4.5 g.<br></p>
<p><span class="Italics">Race</span></p>
<p>There are insufficient data to evaluate any pharmacokinetic differences among races.<br></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>No pharmacokinetic study in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has been conducted.<br></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </span></p>
<p>The pharmacokinetics of Xyrem in 16 cirrhotic patients, half without <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> (Childâ€™s Class A) and half with <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> (Childâ€™s Class C), were compared to the kinetics in 8 subjects with normal hepatic function after a single oral dose of 25 mg/kg. AUC values were double in the cirrhotic patients, with apparent oral clearance reduced from 9.1 mL/min/kg in healthy adults to 4.5 and 4.1 mL/min/kg in Class A and Class C patients, respectively. Elimination half-life was significantly longer in Class C and Class A patients than in control patients (mean t<span class="Sub">1/2</span> of 59 and 32 minutes, respectively, versus 22 minutes). The starting dose of Xyrem should be reduced by one-half in patients with liver impairment <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_id_9e6a98c9-6045-4e23-bfe3-198dc290b14c">2.3</a>); Use in Specific Populations (<a href="#i4i_section_id_61053043-317b-41fc-a311-5ff35d24844c">8.6</a>)].</span><br></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5b96b9a6-18be-4592-ae57-c432af4e6f65"></a><a name="section-12.2.3"></a><p></p>
<h3><span class="Bold">Drug Interactions Studies</span></h3>
<p class="First">Studies <span class="Italics">in vitro</span> with pooled human liver microsomes indicate that sodium oxybate does not significantly inhibit the activities of the human isoenzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A up to the concentration of 3 mM (378 mcg/mL), a level considerably higher than levels achieved with therapeutic doses.<br></p>
<p>Drug interaction studies in healthy adults (age 18 to 50 years) were conducted with Xyrem and divalproex sodium, diclofenac, and ibuprofen:</p>
<dl>
<dt>â€¢</dt>
<dd>Divalproex sodium: Co-administration of Xyrem (6 g per day as two equal doses of 3 grams dosed four hours apart) with divalproex sodium (valproic acid, 1250Â mg per day) increased mean systemic exposure to sodium oxybate as shown by AUC by approximately 25%, while C<span class="Sub">max</span> was comparable.  Co-administration did not appear to affect the pharmacokinetics of valproic acid.  A greater impairment on some tests of attention and working memory was observed with co-administration of both drugs than with either drug alone <span class="Italics">[see Drug Interactions (<a href="#ID_0d200621-9945-4a87-a788-de372a3f01c1">7.2</a>) </span>and<span class="Italics"> Dosage and AdministrationÂ (<a href="#ID_ff9e47b9-8c57-403b-a439-7a15306fb056">2.4</a>)].</span>
</dd>
<dt>â€¢</dt>
<dd>Diclofenac: Co-administration of Xyrem (6 g per day as two equal doses of 3 grams dosed four hours apart) with diclofenac (50 mg/dose twice per day) showed no significant differences in systemic exposure to sodium oxybate. Co-administration did not appear to affect the pharmacokinetics of diclofenac. </dd>
<dt>â€¢</dt>
<dd>Ibuprofen: Co-administration of Xyrem (6 g per day as two equal doses of 3 grams dosed four hours apart) with ibuprofen (800 mg/dose four times per day also dosed four hours apart) resulted in comparable systemic exposure to sodium oxybate as shown by plasma C<span class="Sub">max</span> and AUC values. Co-administration did not affect the pharmacokinetics of ibuprofen.<br>
</dd>
</dl>
<p>Drug interaction studies in healthy adults demonstrated no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> between sodium oxybate and protriptyline hydrochloride, zolpidem tartrate, and modafinil.  Also, there were no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> with the alcohol dehydrogenase inhibitor fomepizole. However, <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interactions</span> with these drugs cannot be ruled out. Alteration of gastric pH with omeprazole produced no significant change in the oxybate kinetics. In addition, drug interaction studies in healthy adults demonstrated no pharmacokinetic or clinically significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interactions</span> between sodium oxybate and the SNRI duloxetine HCl.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_cc5861b4-9a0d-4486-b8b1-ebe292428449"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_3be74fdc-ebc0-43db-8d1b-bf6a2ff3c761"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Italics">Carcinogenesis</span></p>
<p>Administration of sodium oxybate to rats at oral doses of up to 1,000 mg/kg/day for 83Â (males) or 104 (females) weeks resulted in no increase in tumors. Plasma exposure (AUC) at the highest dose tested was 2 times that in humans at the maximum recommended human dose (MRHD) of 9 g per night.</p>
<p>The results of 2-year carcinogenicity studies in mouse and rat with gamma-butyrolactone, a compound that is metabolized to sodium oxybate <span class="Italics">in vivo</span>, showed no clear evidence of carcinogenic activity. The plasma AUCs of sodium oxybate achieved at the highest doses tested in these studies were less than that in humans at the MRHD.</p>
<p><span class="Italics">Mutagenesis</span></p>
<p>Sodium oxybate was negative in the <span class="Italics">in vitro</span> bacterial gene mutation assay, an <span class="Italics">in vitro</span> chromosomal aberration assay in mammalian cells, and in an <span class="Italics">in vivo</span> rat micronucleus assay.</p>
<p><span class="Italics">Impairment of Fertility</span></p>
<p>Oral administration of sodium oxybate (150, 350, or 1,000 mg/kg/day) to male and female rats prior to and throughout mating and continuing in females through early gestation resulted in no adverse effects on fertility. The highest dose tested is approximately equal to the MRHD on a mg/m<span class="Sup">2</span> basis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_fdda75a4-5b40-49bb-8756-152d6f93c6cf"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d9c75604-4c43-45bd-9ab2-2adfca852e6f"></a><a name="section-14.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">Cataplexy</span> in <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">Narcolepsy</span></h2>
<p class="First">The effectiveness of Xyrem in the treatment of <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">cataplexy</span> was established in two randomized, double-blind, placebo-controlled, multicenter, parallel-group trials (Trials N1 and N2) in patients with <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span> (see Table 4). In Trials N1 and N2, 85% and 80% of patients, respectively, were also being treated with CNS stimulants.  The high percentages of concomitant stimulant use make it impossible to assess the efficacy and safety of Xyrem independent of stimulant use.  In each trial, the treatment period was 4 weeks and the total nightly Xyrem doses ranged from 3 g to 9 g, with the total nightly dose administered as two equal doses.  The first dose each night was taken at bedtime and the second dose was taken 2.5 to 4 hours later.  There were no restrictions on the time between food consumption and dosing.</p>
<p>Trial N1 enrolled 136 narcoleptic patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">cataplexy</span> (median of 21 <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">cataplexy</span> attacks per week) at baseline.  Prior to randomization, medications with possible effects on <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">cataplexy</span> were withdrawn, but stimulants were continued at stable doses.  Patients were randomized to receive placebo, Xyrem 3 g per night, Xyrem 6 g per night, or Xyrem 9 g per night.</p>
<p>Trial N2 was a randomized withdrawal trial with 55 narcoleptic patients who had been taking open-label Xyrem for 7 to 44 months prior to study entry. To be included, patients were required to have a history of at least 5 <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">cataplexy</span> attacks per week prior to any treatment for <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">cataplexy</span>. Patients were randomized to continued treatment with Xyrem at their stable dose (ranging from 3 g to 9 g per night) or to placebo for 2 weeks. Trial N2 was designed specifically to evaluate the continued efficacy of sodium oxybate after long-term use.</p>
<p>The primary efficacy measure in Trials N1 and N2 was the frequency of <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">cataplexy</span> attacks.</p>
<p><span class="Bold">Table 4</span></p>
<p><span class="Bold">Median Number of <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">Cataplexy</span> Attacks in Trials N1 and N2</span></p>
<table width="100%">
<col width="34%">
<col width="14%">
<col width="29%">
<col width="18%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Trial/Dosage Group </span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Baseline</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Median Change from Baseline</span></p></td>
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Comparison to Placebo (p-value)</span></p></td>
</tr>
<tr><td class="Botrule" colspan="4" valign="top"><p class="First"><span class="Bold">Trial N1 (Prospective, Randomized, Parallel Group Trial)</span></p></td></tr>
<tr>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">(median attacks/week)</p></td>
<td class="Botrule Lrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">Placebo </span>(n=33)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">20.5</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">-4</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">â€“</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">Xyrem 6 g per night </span>(n=31)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">23.0</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">-10</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">0.0451</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">Xyrem 9 g per night </span>(n=33)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">23.5</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">-16</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">0.0016</p></td>
</tr>
<tr><td class="Botrule" colspan="4" valign="top"><dl>
<dt>Â </dt>
<dd><span class="Bold">	Trial N2 (Randomized Withdrawal Trial)</span></dd>
</dl></td></tr>
<tr>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">(median attacks/2 weeks)</p></td>
<td class="Botrule Lrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">Placebo </span>(n=29)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">4.0</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">21</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">â€“</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">Xyrem </span>(n=26)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">1.9</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">&lt; 0.001</p></td>
</tr>
</tbody>
</table>
<p>In Trial N1, both the 6 g and 9 g per night Xyrem doses resulted in statistically significant reductions in the frequency of <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">cataplexy</span> attacks.  The 3 g per night dose had little effect. In Trial N2, patients randomized to placebo after discontinuing long-term open-label Xyrem therapy experienced a significant increase in <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">cataplexy</span> attacks (p &lt; 0.001), providing evidence of long-term efficacy of Xyrem.  In Trial N2, the response was numerically similar for patients treated with doses of 6 g to 9 g per night, but there was no effect seen in patients treated with doses less than 6 g per night, suggesting little effect at these doses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3f4dc2ed-beb5-452e-867d-03c2496fb777"></a><a name="section-14.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Excessive Daytime Sleepiness</span> in <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">Narcolepsy</span></h2>
<p class="First">The effectiveness of Xyrem in the treatment of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">excessive daytime sleepiness</span> in patients with <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span> was established in two randomized, double-blind, placebo-controlled trials (Trials N3 and N4) (see Tables 5 to 7). Seventy-eight percent of patients in Trial N3 were also being treated with CNS stimulants.</p>
<p>Trial N3 was a multicenter randomized, double-blind, placebo-controlled, parallel-group trial that evaluated 228 patients with moderate to severe symptoms at entry into the study including a median Epworth <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Sleepiness</span> Scale (see below) score of 18, and a Maintenance of <span class="product-label-link" type="condition" conceptid="4100068" conceptname="Wakefulness">Wakefulness</span> Test (see below) score of 8.3 minutes. Patients were randomized to one of 4 treatment groups: placebo, Xyrem 4.5 g per night, Xyrem 6 g per night, or Xyrem 9 g per night. The period of double-blind treatment in this trial was 8 weeks. Antidepressants were withdrawn prior to randomization; stimulants were continued at stable doses.</p>
<p>The primary efficacy measures in Trial N3 were the Epworth <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Sleepiness</span> Scale and the Clinical Global Impression of Change. The Epworth <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Sleepiness</span> Scale is intended to evaluate the extent of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> in everyday situations by asking the patient a series of questions. In these questions, patients were asked to rate their chances of dozing during each of 8 activities on a scale from 0-3 (0=never; 1=slight; 2=moderate; 3=high). Higher total scores indicate a greater tendency to <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>. The Clinical Global Impression of Change is evaluated on a 7-point scale, centered at <span class="Italics">No Change</span>, and ranging from <span class="Italics">Very Much Worse </span>to <span class="Italics">Very Much Improved</span>. In Trial N3, patients were rated by evaluators who based their assessments on the severity of <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span> at baseline.</p>
<p>In Trial N3, statistically significant improvements were seen on the Epworth <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Sleepiness</span> Scale score at Week 8 and on the Clinical Global Impression of Change score at Week 8 with the 6 g and 9 g per night doses of Xyrem compared to the placebo group.</p>
<p><span class="Bold">Table 5 </span></p>
<p><span class="Bold">Change from Baseline in <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Daytime Sleepiness</span> Score (Epworth <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Sleepiness</span> Scale) at Week 8 in Trial N3 (Range 0-24)</span></p>
<table width="100%">
<col width="20%">
<col width="14%">
<col width="15%">
<col width="20%">
<col width="26%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Treatment Group</span><br></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Baseline</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Week 8</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Median Change from Baseline at Week 8</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><br><span class="Bold">p-value</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span> (n=59)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">17.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">17.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-0.5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Xyrem 6 g per night </span>(n=58)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">19.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">16.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-2.0</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 0.001</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Xyrem 9 g per night</span> (n=47)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">19.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-5.0</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 0.001</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Table 6</span></p>
<p><span class="Bold">Proportion of patients with a very much or much improved Clinical Global Impression of Change in Daytime and Nighttime Symptoms in Trial N3</span></p>
<table width="100%">
<col width="31%">
<col width="33%">
<col width="32%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Treatment Group </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Percentages of Responders</span><br><span class="Bold">(Very Much Improved or Much Improved)</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Change from Baseline </span></p>
<p><span class="Bold">Significance Compared to Placebo</span><br><span class="Bold">(p-value)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span> (59)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">22%</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Xyrem 6 g per night</span> (n=58)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">52%</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 0.001</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Xyrem 9 g per night</span> (n=47)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">64%</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 0.001</p></td>
</tr>
</tbody>
</table>
<p>Trial N4 was a multicenter randomized, double-blind, placebo-controlled, parallel-group trial that evaluated 222 patients with moderate to severe symptoms at entry into the study including a median Epworth <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Sleepiness</span> Scale score of 15, and a Maintenance of <span class="product-label-link" type="condition" conceptid="4100068" conceptname="Wakefulness">Wakefulness</span> Test (see below) score of 10.3 minutes. At entry, patients had to be taking modafinil at stable doses of 200 mg, 400 mg, or 600 mg daily for at least 1 month prior to randomization. The patients enrolled in the study were randomized to one of 4 treatment groups: placebo, Xyrem, modafinil, or Xyrem plus modafinil. Xyrem was administered in a dose of 6 g per night for 4 weeks, followed by 9 g per night for 4 weeks. Modafinil was continued in the modafinil alone and the Xyrem plus modafinil treatment groups at the patientâ€™s prior dose.  Trial N4 was not designed to compare the effects of Xyrem to modafinil because patients receiving modafinil were not titrated to a maximal dose. Patients randomized to placebo or to Xyrem treatment were withdrawn from their stable dose of modafinil. Patients taking antidepressants could continue these medications at stable doses.</p>
<p>The primary efficacy measure in Trial N4 was the Maintenance of <span class="product-label-link" type="condition" conceptid="4100068" conceptname="Wakefulness">Wakefulness</span> Test. The Maintenance of <span class="product-label-link" type="condition" conceptid="4100068" conceptname="Wakefulness">Wakefulness</span> Test measures latency to sleep onset (in minutes) averaged over 4 sessions at 2-hour intervals following nocturnal polysomnography. For each test session, the subject was asked to remain awake without using extraordinary measures. Each test session is terminated after 20 minutes if no sleep occurs, or after 10 minutes, if sleep occurs. The overall score is the mean sleep latency for the 4 sessions. </p>
<p>In Trial N4, a statistically significant improvement in the change in the Maintenance of <span class="product-label-link" type="condition" conceptid="4100068" conceptname="Wakefulness">Wakefulness</span> Test score from baseline at Week 8 was seen in the Xyrem and Xyrem plus modafinil groups compared to the placebo group.</p>
<p>This trial was not designed to compare the effects of Xyrem to modafinil, because patients receiving modafinil were not titrated to a maximally effective dose.</p>
<p><span class="Bold">Table 7</span></p>
<p><span class="Bold">Change in Baseline in the Maintenance of <span class="product-label-link" type="condition" conceptid="4100068" conceptname="Wakefulness">Wakefulness</span> Test Score (in minutes) at WeekÂ 8 in Trial N4</span></p>
<table width="100%">
<col width="21%">
<col width="14%">
<col width="15%">
<col width="20%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Treatment Group </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Baseline</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Week 8</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Mean Change from Baseline at Week 8</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"> p-value</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Placebo (modafinil withdrawn) </span>(n=55)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">9.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-2.7</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Xyrem (modafinil withdrawn) </span>(n=50)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">11.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 0.001</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Xyrem plus modafinil</span> (n=54)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">10.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">13.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.7</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">&lt; 0.001</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_e0b14c6d-8006-4433-a60a-3da2a5a5b2fe"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_56f60fe7-3be7-4978-ad07-cb21a32bd974"></a><a name="section-15.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">Xyrem is a clear to slightly opalescent oral solution. Each prescription includes a carton containing one bottle of Xyrem, a press-in-bottle-adaptor, an oral measuring device (plastic syringe), and a Medication Guide. The pharmacy provides two empty vials with child-resistant caps with each Xyrem shipment.</p>
<p>Each amber bottle contains Xyrem oral solution at a concentration of 0.5 g per mL and has a child-resistant cap.</p>
<p>Carton containing one 180 mL bottleÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â NDC 68727-100-01</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c206ab3c-11ae-4845-8db3-774c06befbd4"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Storage</h2>
<p class="First"><span class="Bold">Keep out of reach of children.</span><br><br>Xyrem should be stored at 25Â°C (77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) (see USP Controlled Room Temperature).<br><br>Dispense in tight containers.<br><br>Solutions prepared following dilution should be consumed within 24 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_15e30dfd-9dde-490a-9a86-5ea4e8654d0f"></a><a name="section-15.3"></a><p></p>
<h2>16.3 Handling and Disposal</h2>
<p class="First">Xyrem is a Schedule III drug under the Controlled Substances Act. Xyrem should be handled according to state and federal regulations. It is safe to dispose of Xyrem down the sanitary sewer.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_c73f7472-bf36-4178-99b3-76a4959d390c"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labeling (Medication Guide).</p>
<p><span class="Bold">Xyrem REMS Program</span></p>
<p>Inform patients that Xyrem is available only through a restricted distribution program called the Xyrem REMS Program.</p>
<p>The contents of the Xyrem Medication Guide and educational materials are reviewed with every patient before initiating treatment with Xyrem.</p>
<p>Patients must read and understand the materials in the Xyrem REMS Program prior to initiating treatment. Inform the patient that they should be seen by the prescriber frequently to review dose titration, symptom response, and adverse reactions; a follow-up of every three months is recommended.</p>
<p>Discuss safe and proper use of Xyrem and dosing information with patients prior to the initiation of treatment. Instruct patients to store Xyrem bottles and Xyrem doses in a secure place, out of the reach of children and pets.</p>
<p><span class="Bold">Alcohol or Sedative Hypnotics</span></p>
<p>Advise patients not to drink alcohol or take other sedative hypnotics if they are taking Xyrem.</p>
<p><span class="Bold">Sedation</span></p>
<p>Inform patients that after taking Xyrem they are likely to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep quickly (often within 5 and usually within 15 minutes), but the time it takes to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep can vary from night to night.  The sudden onset of sleep, including in a standing position or while rising from bed, has led to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> complicated by injuries, in some cases requiring hospitalization.  Instruct patients to remain in bed following ingestion of the first and second doses. Instruct patients not to take their second dose until 2.5 to 4 hours after the first dose. </p>
<p><span class="Bold">Food Effects on Xyrem</span></p>
<p>Inform patients to take the first dose at least 2 hours after eating. </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></span></p>
<p>Inform patients that Xyrem can be associated with <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
<p><span class="Bold">Operating Hazardous Machinery</span></p>
<p>Inform patients that until they are reasonably certain that Xyrem does not affect them adversely (e.g., impair judgment, thinking, or motor skills) they should not operate hazardous machinery, including automobiles or airplanes.</p>
<p><span class="Bold">Suicidality</span></p>
<p>Instruct patients or families to contact a healthcare provider immediately if the patient develops <span class="product-label-link" type="condition" conceptid="40546087" conceptname="Depressed mood">depressed mood</span>, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">psychomotor agitation</span> or retardation, increased <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, feelings of guilt or worthlessness, <span class="product-label-link" type="condition" conceptid="4111210" conceptname="Bradyphrenia">slowed thinking</span> or impaired concentration, or <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>.</p>
<p><span class="Bold">Sleepwalking</span></p>
<p>Instruct patients and their families that Xyrem has been associated with sleepwalking and to contact their healthcare provider if this occurs.</p>
<p><span class="Bold">Sodium Intake</span></p>
<p>Instruct patients who are sensitive to salt intake (e.g., those with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>) that Xyrem contains a significant amount of sodium and they should limit their sodium intake.<br><br><span class="Bold">Distributed By:</span><br><br>Jazz Pharmaceuticals, Inc.<br>Palo Alto, CA 94304<br><br>Protected by U.S. Patent Nos. 6,472,431; 6,780,889; 7,262,219; 7,851,506; 8,263,650; 8,324,275; 8,461,203; 8,772,306; 8,859,619; 8,952,062</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="i4i_medguide_id_6a8b132a-187e-4a94-9d30-5fde8ef013ee"></a><a name="section-17"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">Xyrem<span class="Sup">Â®</span> (ZÄªE-rem)</span></p>
<p><span class="Bold">(sodiumÂ oxybate)</span></p>
<p><span class="Bold">oral solution CIII</span></p>
<p>Read this Medication Guide carefully before you start taking Xyrem and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment. </p>
<p><span class="Bold">What is the most important information I should know about Xyrem? </span></p>
<p><span class="Bold">Xyrem can cause serious side effects </span>including slow breathing or changes in your alertness.  Do not drink alcohol or take medicines intended to make you <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep while you are taking Xyrem because they can make these side effects worse. Call your doctor right away if you have any of these serious side effects. </p>
<dl>
<dt>â€¢</dt>
<dd>The active ingredient of Xyrem is a form of gamma-hydroxybutyrate (GHB). GHB is a chemical that has been abused and misused. Abuse and misuse of Xyrem can cause serious medical problems, including:<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></dd>
<dt>â€¢</dt>
<dd>trouble breathing </dd>
<dt>â€¢</dt>
<dd>changes in alertness</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>Do not drive a car, use heavy machinery, fly an airplane, or do anything that is dangerous or that requires you to be fully awake for at least 6 hours after you take Xyrem. You should not do those activities until you know how Xyrem affects you.</dd>
<dt>â€¢</dt>
<dd>Xyrem is available only by prescription and filled through the central pharmacy in the Xyrem REMS Program. Before you receive Xyrem, your doctor or pharmacist will make sure that you understand how to use Xyrem safely and effectively. If you have any questions about Xyrem, ask your doctor or call the Xyrem REMS Program at 1-866-997-3688. </dd>
</dl>
<p><span class="Bold">What is Xyrem?</span></p>
<p>Xyrem is a prescription medicine used to treat the following symptoms in people who <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep frequently during the day, often at unexpected times (<span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span>):  </p>
<dl>
<dt>â€¢</dt>
<dd>suddenly weak or <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralyzed</span> muscles when they feel strong emotions (<span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">cataplexy</span>) </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">excessive daytime sleepiness</span> (EDS) in people who have <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span></dd>
</dl>
<p>It is not known if Xyrem is safe and effective in children.</p>
<p>Xyrem is a controlled substance (CIII) because it contains sodium oxybate that can be a target for people who abuse prescription medicines or street drugs. Keep your Xyrem in a safe place to protect it from <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">theft</span>. Never give your Xyrem to anyone else because it may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or harm them. Selling or giving away this medicine is against the law.  </p>
<p><span class="Bold">Who should not take Xyrem? </span></p>
<p><span class="Bold">Do not take Xyrem if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>take other sleep medicines or sedatives (medicines that cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>)</dd>
<dt>â€¢</dt>
<dd>drink alcohol </dd>
<dt>â€¢</dt>
<dd>have a rare problem called succinic semialdehyde dehydrogenase deficiency</dd>
</dl>
<p><span class="Bold">Before you take Xyrem, tell your doctor if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>have short periods of not breathing while you sleep (<span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4248728" conceptname="Snoring">snore</span>, have trouble breathing, or have lung problems. You may have a higher chance of having serious breathing problems when you take Xyrem.</dd>
<dt>â€¢</dt>
<dd>have or had <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or have tried to harm yourself.  You should be watched carefully for new symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</dd>
<dt>â€¢</dt>
<dd>have liver problems </dd>
<dt>â€¢</dt>
<dd>are on a salt-restricted diet.  Xyrem contains a lot of sodium (salt) and may not be right for you.</dd>
<dt>â€¢</dt>
<dd>have high blood pressure</dd>
<dt>â€¢</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></dd>
<dt>â€¢</dt>
<dd>have kidney problems </dd>
<dt>â€¢</dt>
<dd>are pregnant or plan to become pregnant. It is not known if Xyrem can harm your unborn baby.</dd>
<dt>â€¢</dt>
<dd>are breastfeeding or plan to breastfeed. It is not known if Xyrem passes into your breast milk. You and your doctor should decide if you will take Xyrem or breastfeed. </dd>
</dl>
<p><span class="Bold">Tell your doctor about all the medicines you take,</span> including prescription and non-prescription medicines, vitamins, and herbal supplements. </p>
<p>Especially, tell your doctor if you take other medicines to help you sleep (sedatives). Do not take medicines that make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> with Xyrem.</p>
<p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take Xyrem?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Read the <span class="Bold">Instructions for Use</span> at the end of this Medication Guide for detailed instructions on how to take Xyrem. </dd>
<dt>â€¢</dt>
<dd>Take Xyrem exactly as your doctor tells you to take it.</dd>
<dt>â€¢</dt>
<dd>Never change your Xyrem dose without talking to your doctor.</dd>
<dt>â€¢</dt>
<dd>Xyrem can cause sleep very quickly. You should <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep soon.  Some patients <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep within 5 minutes and most <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep within 15Â minutes.  Some patients take less time to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep and some take more time.  The time it takes you to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep might be different from night to night. </dd>
<dt>â€¢</dt>
<dd>Take your first Xyrem dose at bedtime while you are in bed. Take your second Xyrem dose 2 Â½ to 4 hours after you take your first Xyrem dose. You may want to set an alarm clock to make sure you wake up to take your second Xyrem dose. You should remain in bed after taking the first and second doses of Xyrem.</dd>
<dt>â€¢</dt>
<dd>If you miss your second Xyrem dose, skip that dose and do not take Xyrem again until the next night. Never take 2 Xyrem doses at 1 time.</dd>
<dt>â€¢</dt>
<dd>Wait at least 2 hours after eating before you take Xyrem.  </dd>
<dt>â€¢</dt>
<dd>You should see your doctor every 3 months for a check-up while taking Xyrem. Your doctor should check to see if Xyrem is helping to lessen your symptoms and if you feel any side effects while you take Xyrem.</dd>
<dt>â€¢</dt>
<dd>If you take too much Xyrem, call your doctor or go to the nearest hospital emergency room right away. </dd>
</dl>
<p><span class="Bold">What are the possible side effects of Xyrem?</span></p>
<p><span class="Bold">Xyrem can cause serious side effects, including:</span></p>
<dl>
<dt>â€¢</dt>
<dd>See <span class="Bold">â€œWhat is the most important information I should know about Xyrem?â€?</span>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Breathing problems, including: </span><dl>
<dt>â€¢</dt>
<dd>slower breathing</dd>
<dt>â€¢</dt>
<dd>trouble breathing</dd>
<dt>â€¢</dt>
<dd>short periods of not breathing while sleeping (<span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span>). People who already have breathing or lung problems have a higher chance of having breathing problems when they use Xyrem.</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Mental health problems, including: </span><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> </dd>
<dt>â€¢</dt>
<dd>seeing or hearing things that are not real (<span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>)</dd>
<dt>â€¢</dt>
<dd>unusual or disturbing thoughts (<span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span>)</dd>
<dt>â€¢</dt>
<dd>feeling anxious or upset</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></dd>
<dt>â€¢</dt>
<dd>thoughts of killing yourself or trying to kill yourself</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">Call your doctor right away if you have symptoms of mental health problems.</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Sleepwalking.</span> Sleepwalking can cause injuries. Call your doctor if you start sleepwalking. Your doctor should check you. </dd>
</dl>
<p>The most common side effects of Xyrem include:</p>
<dl>
<dt>Â </dt>
<dd><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
<dt>â€¢</dt>
<dd>bedwetting</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
</dl></dd>
</dl>
<p>Your side effects may increase when you take higher doses of Xyrem. </p>
<p>Xyrem can cause physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and craving for the medicine when it is not taken as directed. </p>
<p>These are not all the possible side effects of Xyrem. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store Xyrem?</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Always store Xyrem in the original bottle or in pharmacy containers with child-resistant caps provided by the pharmacy.</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Keep Xyrem in a safe place out of the reach of children and pets. </span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Get emergency medical help right away if a child drinks your Xyrem. </span></dd>
<dt>â€¢</dt>
<dd>Store Xyrem between 68Â°F to 77Â°F (20Â°C to 24Â°C). When you have finished using a Xyrem bottle:<dl>
<dt>â€¢</dt>
<dd>empty any unused Xyrem down the sink drain</dd>
<dt>â€¢</dt>
<dd>cross out the label on the Xyrem bottle with a marker</dd>
<dt>â€¢</dt>
<dd>place the empty Xyrem bottle in the trash</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">General information about the safe and effective use of Xyrem</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Xyrem for a condition for which it was not prescribed.  Do not give Xyrem to other people, even if they have the same symptoms that you have.  It may harm them. </p>
<p>This Medication Guide summarizes the most important information about Xyrem.  If you would like more information, talk with your doctor.  You can ask your pharmacist or doctor for information about Xyrem that is written for health professionals. </p>
<p>For more information, go to <a href="http://www.XYREMREMS.com">www.XYREMREMS.com</a> or call the Xyrem REMS Program at 1-866-997-3688. </p>
<p><span class="Bold">What are the ingredients in Xyrem?</span><br>Active Ingredients: sodium oxybate</p>
<p>Inactive Ingredients: purified water and malic acid </p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.<br><br><span class="Bold">Distributed By:</span><br><br>Jazz Pharmaceuticals, Inc.<br>Palo Alto, CA 94304<br><br>Revised: April 2015<br><br></p>
<div class="Section" data-sectionCode="59845-8">
<a name="ID_8f4934bb-fb18-4855-ac6f-a456220bef12"></a><a name="section-17.1"></a><p></p>
<h2>Instructions for Use</h2>
<p class="First"><span class="Bold">Xyrem<span class="Sup">Â® </span>(ZÄªE-rem)</span></p>
<p><span class="Bold">(sodiumÂ oxybate)</span></p>
<p><span class="Bold">oral solution CIII</span></p>
<p>Read these Instructions for Use carefully before you start taking Xyrem and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment. </p>
<p><span class="Bold">Note: </span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">You will need to split your prescribed Xyrem dose into 2 separate pharmacy containers for mixing.</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">You will need to mix Xyrem with water before you take your dose.</span></dd>
<dt>â€¢</dt>
<dd>Take your dose within 24 hours after mixing Xyrem with water. If you do not take your dose within this time, you will need to throw the mixture away.</dd>
</dl>
<p>Supplies you will need for mixing and taking Xyrem: See Figure A.</p>
<dl>
<dt>â€¢</dt>
<dd>bottle of your Xyrem medicine </dd>
<dt>â€¢</dt>
<dd>press-in-bottle-adaptor with straw attached </dd>
<dt>â€¢</dt>
<dd>syringe for drawing up your Xyrem dose</dd>
<dt>â€¢</dt>
<dd>a measuring cup containing about Â¼ cup of water (not provided with your Xyrem prescription)</dd>
<dt>â€¢</dt>
<dd>2 <span class="Bold">empty</span> pharmacy containers with child-resistant caps </dd>
<dt>â€¢</dt>
<dd>alarm clock by your bedside (alarm clock may be included in your first shipment of Xyrem)</dd>
</dl>
<div class="Figure">
<a name="id452828352"></a><img alt="Figure A" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=926eb076-a4a8-45e4-91ef-411f0aa4f3ca&amp;name=image-02.jpg">
</div>
<p><span class="Bold">Figure A</span></p>
<p><span class="Bold">Step 1. </span>Take the Xyrem bottle, press-in-bottle-adaptor, and syringe out of the box. </p>
<p><span class="Bold">Step 2.</span> Remove the bottle cap from the Xyrem bottle by pushing down while turning the cap counterclockwise (to the left). See Figure B. </p>
<div class="Figure">
<a name="id-765537851"></a><img alt="Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=926eb076-a4a8-45e4-91ef-411f0aa4f3ca&amp;name=image-03.jpg">
</div>
<p><span class="Bold">Figure B</span></p>
<p><span class="Bold">Step 3.</span></p>
<dl>
<dt>â€¢</dt>
<dd>The press-in-bottle-adaptor may already be put in place by the pharmacy. If it is not already in place, you will have to do it yourself. After removing the cap from the Xyrem bottle, set the bottle upright on a tabletop. </dd>
<dt>â€¢</dt>
<dd>While holding the Xyrem bottle in its upright position, insert the press-in-bottle-adaptor into the neck of the Xyrem bottle. See Figure C.</dd>
</dl>
<div class="Figure">
<a name="id-779884771"></a><img alt="Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=926eb076-a4a8-45e4-91ef-411f0aa4f3ca&amp;name=image-04.jpg">
</div>
<p><span class="Bold">Figure C</span></p>
<dl>
<dt>â€¢</dt>
<dd>Tilt the straw toward the edge of the bottom of the bottle to be sure you can draw out your dose of the medicine. You only need to do this the first time you open the bottle. See Figure D. </dd>
</dl>
<div class="Figure">
<a name="id-1340457578"></a><img alt="Figure D" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=926eb076-a4a8-45e4-91ef-411f0aa4f3ca&amp;name=image-05.jpg">
</div>
<p><span class="Bold">Figure D</span></p>
<dl>
<dt>â€¢</dt>
<dd>After you draw out your dose of the medicine, leave the adaptor in the bottle for all your future uses. See Figure E. </dd>
</dl>
<div class="Figure">
<a name="id-212116416"></a><img alt="Figure E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=926eb076-a4a8-45e4-91ef-411f0aa4f3ca&amp;name=image-06.jpg">
</div>
<p><span class="Bold">Figure E</span></p>
<p><span class="Bold">Step 4</span>.</p>
<dl>
<dt>â€¢</dt>
<dd>Take the syringe out of the plastic wrapper. Use only the syringe provided with your Xyrem prescription. </dd>
<dt>â€¢</dt>
<dd>While holding the Xyrem bottle upright on the tabletop, insert the tip of the syringe into the opening on top of the Xyrem bottle and press down firmly. See Figure F. </dd>
</dl>
<div class="Figure">
<a name="id1820076851"></a><img alt="Figure F" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=926eb076-a4a8-45e4-91ef-411f0aa4f3ca&amp;name=image-07.jpg">
</div>
<p><span class="Bold">Figure F </span></p>
<p><span class="Bold">Step 5.</span></p>
<dl>
<dt>â€¢</dt>
<dd>Hold the bottle and syringe down with one hand, and draw up one-half (1/2) of your total prescribed nightly dose with the other hand by pulling up on the plunger. For example, if your total nightly dose of Xyrem is 4.5 grams a night, you will need to draw up 2 separate doses of 2.25 grams each, one for each pharmacy container.  See Figure G.</dd>
</dl>
<p><span class="Bold">Note</span>: <span class="Bold">The Xyrem medicine will not flow into the syringe unless you keep the bottle upright.</span></p>
<div class="Figure">
<a name="id-2045133265"></a><img alt="Figure G" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=926eb076-a4a8-45e4-91ef-411f0aa4f3ca&amp;name=image-08.jpg">
</div>
<p><span class="Bold">Figure G</span></p>
<p><span class="Bold">Step 6</span>. </p>
<dl>
<dt>â€¢</dt>
<dd>After you draw up each separate Xyrem dose, remove the syringe from the opening of the Xyrem bottle. Put the tip into 1 of the <span class="Bold">empty</span> containers with child-resistant caps provided by the pharmacy. </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Make sure the pharmacy container is empty and does not contain any medicine from your previous nightâ€™s dose. </span><dl>
<dt>â€¢</dt>
<dd>Empty each separate Xyrem dose into 1 of the <span class="Bold">empty</span> pharmacy containers by pushing down on the plunger. (See Figure H). </dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>Using a measuring cup, pour about Â¼ cup of water into <span class="Bold">each </span>container. <span class="Bold">Be careful to add only water to each container and not more Xyrem. All shipped bottles of Xyrem contain the concentrated medicine. Water for mixing the medicine is not provided in the shipment.</span>
</dd>
</dl>
<div class="Figure">
<a name="id1923834944"></a><img alt="Figure H" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=926eb076-a4a8-45e4-91ef-411f0aa4f3ca&amp;name=image-09.jpg">
</div>
<p><span class="Bold">Figure H</span></p>
<p><span class="Bold">Step 7.</span></p>
<dl>
<dt>â€¢</dt>
<dd>Place the child-resistant caps provided on the filled pharmacy containers and turn each cap clockwise (to the right) until it clicks and locks into its child-resistant position. See Figure I.</dd>
</dl>
<div class="Figure">
<a name="id1443043124"></a><img alt="Figure I" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=926eb076-a4a8-45e4-91ef-411f0aa4f3ca&amp;name=image-10.jpg">
</div>
<p><span class="Bold">Figure I </span></p>
<dl>
<dt>â€¢</dt>
<dd>Put the cap back on the Xyrem bottle and store it in a safe and secure place. Store in a locked place if needed. Keep Xyrem out of the reach of children and pets.  </dd>
<dt>â€¢</dt>
<dd>Rinse the syringe out with water and squirt the liquid into the sink drain.</dd>
</dl>
<p><span class="Bold">Step 8</span>.</p>
<dl>
<dt>â€¢</dt>
<dd>At bedtime, and before you take your first Xyrem dose, put your second Xyrem dose in a safe place near your bed. </dd>
<dt>â€¢</dt>
<dd>You may want to set an alarm clock to make sure you wake up to take the second dose. </dd>
<dt>â€¢</dt>
<dd>When it is time to take your first Xyrem dose, remove the cap from the container by pressing down on the child-resistant locking tab and turning the cap counterclockwise (to the left). </dd>
<dt>â€¢</dt>
<dd>Drink all of your first Xyrem dose at bedtime. Put the cap back on the first container before lying down to sleep. </dd>
<dt>â€¢</dt>
<dd>You should <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep soon.  Some patients <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep within 5 minutes and most <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep within 15 minutes.  Some patients take less time to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep, and some take more time.  The time it takes you to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep might be different from night to night. </dd>
</dl>
<p><span class="Bold">Step 9.</span></p>
<dl>
<dt>â€¢</dt>
<dd>When you wake up 2Â½ to 4 hours later, take the cap off the second pharmacy container.  </dd>
<dt>â€¢</dt>
<dd>If you wake up before the alarm and it has been at least 2Â½ hours since your first Xyrem dose, turn off your alarm and take your second Xyrem dose. </dd>
<dt>â€¢</dt>
<dd>While sitting in bed, drink all of the second Xyrem dose and put the cap back on the second pharmacy container before lying down to continue sleeping.  </dd>
</dl>
<p><span class="Bold">Distributed By:</span><br><br>Jazz Pharmaceuticals, Inc.<br>Palo Alto, CA 94304<br><br>These Instructions for Use have been approved by the U.S. Food and Drug Administration.<br><br>Revised: April 2015<br><br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_31eadadd-21d8-474f-9577-67749b709a66"></a><a name="section-18"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id1625660143"></a><img alt="bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=926eb076-a4a8-45e4-91ef-411f0aa4f3ca&amp;name=bottle%20label.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>XYREMÂ 		
					</strong><br><span class="contentTableReg">sodium oxybate solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68727-100</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SODIUM OXYBATE</strong> (4-HYDROXYBUTANOIC ACID) </td>
<td class="formItem">SODIUM OXYBATE</td>
<td class="formItem">0.5Â g Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68727-100-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">180 mL in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021196</td>
<td class="formItem">07/17/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Jazz Pharmaceuticals, Inc.
							(135926363)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Jazz Pharmaceuticals, Inc. (135926363)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Jazz Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">135926363</td>
<td class="formItem">MANUFACTURE(68727-100)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1e24d56e-1715-4373-a379-04e8fe7dae67</div>
<div>Set id: 926eb076-a4a8-45e4-91ef-411f0aa4f3ca</div>
<div>Version: 9</div>
<div>Effective Time: 20150402</div>
</div>
</div>Â <div class="DistributorName">Jazz Pharmaceuticals, Inc.</div></p>
</body></html>
